Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries.

PLoS Pathogens
Arun K KashyapRamesh R Bhatt

Abstract

Influenza viruses elude immune responses and antiviral chemotherapeutics through genetic drift and reassortment. As a result, the development of new strategies that attack a highly conserved viral function to prevent and/or treat influenza infection is being pursued. Such novel broadly acting antiviral therapies would be less susceptible to virus escape and provide a long lasting solution to the evolving virus challenge. Here we report the in vitro and in vivo activity of a human monoclonal antibody (A06) against two isolates of the 2009 H1N1 pandemic influenza virus. This antibody, which was obtained from a combinatorial library derived from a survivor of highly pathogenic H5N1 infection, neutralizes H5N1, seasonal H1N1 and 2009 "Swine" H1N1 pandemic influenza in vitro with similar potency and is capable of preventing and treating 2009 H1N1 influenza infection in murine models of disease. These results demonstrate broad activity of the A06 antibody and its utility as an anti-influenza treatment option, even against newly evolved influenza strains to which there is limited immunity in the general population.

References

Jan 1, 1989·Proteins·G M Air, W G Laver
Sep 21, 2000·Antiviral Research·L A Sawyer
Feb 10, 2004·Theoretical Population Biology·Maciej F BoniFreddy B Christiansen
Aug 31, 2006·Annals of Internal Medicine·Thomas C LukeStephen L Hoffman
Oct 19, 2007·Journal of Virology·Yiming BaoDavid Lipman
Apr 17, 2008·Proceedings of the National Academy of Sciences of the United States of America·Arun K KashyapRichard A Lerner
Nov 4, 2008·Current Opinion in Infectious Diseases·Angie LackenbyJane Democratis
Feb 24, 2009·Nature Structural & Molecular Biology·Jianhua SuiWayne A Marasco
Mar 3, 2009·Science·Damian C EkiertIan A Wilson
Mar 28, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gregory A PolandInna G Ovsyannikova
Jun 16, 2009·BMJ : British Medical Journal·John Zarocostas
Jun 23, 2009·Science·Jon Cohen, Martin Enserink
Aug 5, 2009·Infection and Immunity·Luisa W ChengJames D Marks
Nov 11, 2009·Science·Andrew W ParkBryan T Grenfell

❮ Previous
Next ❯

Citations

Jan 5, 2014·The Journal of Microbiology·Jin Il KimMan-Seong Park
Apr 5, 2014·Cellular and Molecular Life Sciences : CMLS·Arianna LoregianGiorgio Palù
Feb 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Natalie PicaPeter Palese
Oct 3, 2012·Proceedings of the National Academy of Sciences of the United States of America·Peter S LeeIan A Wilson
Jun 5, 2013·Indian Journal of Virology : an Official Organ of Indian Virological Society·Madhu KhannaPrashant Kumar
Jun 6, 2013·Virus Research·Guus F Rimmelzwaan, Jacqueline M Katz
Sep 10, 2014·Viruses·Yo Han Jang, Baik Lin Seong
Jan 18, 2011·Expert Opinion on Investigational Drugs·Aarthi NarayananKylene Kehn-Hall
Oct 29, 2011·Current Opinion in Virology·Jonathan W Yewdell
Apr 16, 2013·Antiviral Research·Nick S Laursen, Ian A Wilson
Sep 12, 2014·Journal of Bioinformatics and Computational Biology·Jing RenJinyan Li
Mar 19, 2015·BioMed Research International·Anwar M Hashem
Mar 19, 2014·Current Opinion in Immunology·Greg A Kirchenbaum, Ted M Ross
Sep 4, 2012·International Journal of Molecular Sciences·Nicola ClementiRoberto Burioni
Oct 4, 2017·Science·Rameshwar U KadamIan A Wilson
Dec 25, 2019·Cold Spring Harbor Perspectives in Medicine·Nicholas C Wu, Ian A Wilson
Feb 6, 2017·Cold Spring Harbor Perspectives in Biology·Peter D Kwong
Jul 16, 2020·Vaccines·Sabari Nath NeerukondaCarol D Weiss
May 23, 2021·The Journal of Immunology : Official Journal of the American Association of Immunologists·Adam M SandorJenny P Y Ting
Jun 23, 2021·The Journal of Clinical Investigation·Seth J ZostJames E Crowe

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation

Software Mentioned

GraphPad Prism
MUSCLE

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.